Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of gemcitabine with or without IMM-101 in advanced pancreatic cancer
2010-022757-42Phase 2Completed
- Sponsor
- Immodulon Therapeutics
- Start
- Feb 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of IMM-101 in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Immodulon Therapeutics. Primary endpoint: Primary safety endpoint. Started Feb 2011; status: completed.
02
Drugs
IMM-101
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2010-022757-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022757-42.